D-Crypt™
A Robust Platform for Rapid and Scalable Development of Next-Gen Vaccines
Gen Vaccines
D-CryptTM is our proprietary yeast-based platform for Virus-Like Particle (VLP) circRNA-VLP based vaccines, designed to accelerate the development of vaccines against infectious diseases, emerging pathogens, and challenging therapeutic targets.
By combining advanced protein engineering with scalable microbial manufacturing, D-Crypt™ enables tunable display of antigens on highly immunogenic VLP scaffolds, creating potent vaccine candidates that drive robust humoral and cellular immune responses.
The Evolution of D-Crypt™
D-Crypt™ has evolved into a versatile platform engineered to address some of the most significant challenges in biologics, vaccines, and RNA therapeutics. Built on over two decades of protein engineering and vaccine development expertise, the platform now spans three complementary technology modules.
D-Crypt™ Expression Engine: Enabling Complex and Difficult-to-Express Proteins
The foundation of the D-Crypt™ platform was established to overcome bottlenecks in the expression of structurally complex recombinant proteins, including membrane proteins, viral antigens, and other challenging therapeutic targets.
Key capabilities
- + High-yield recombinant protein production
- + Expression of structurally complex and membrane-associated proteins
- + Accelerated antigen discovery and development
- + Scalable microbial manufacturing
D-Crypt™ VLP Platform: Engineering Next-Generation Virus-Like Particle Vaccines
Building on its protein engineering capabilities, D-Crypt™ was expanded to support the coordinated expression and assembly of multiple viral antigens into highly immunogenic Virus-Like Particles (VLPs).
These non-infectious particles closely mimic the structural architecture of native viruses, enabling robust immune responses while maintaining a favourable safety profile.
Applications
- + Infectious disease vaccines
- + Pandemic preparedness programs
- + Multivalent vaccine development
- + Global health vaccine initiatives
D-Crypt™ circRNA-VLP Platform: Converging RNA Medicine and VLP Delivery
The latest evolution of D-Crypt™ integrates circular RNA (circRNA) technology with proprietary VLP delivery systems to create a next-generation platform for vaccines and therapeutics.
By combining the stability advantages of circRNA with the targeted delivery and immunogenic properties of VLPs, the platform is designed to enable durable protein expression and delivery of complex multi-gene payloads.
Applications
- + Next-generation RNA vaccines
- + Cancer immunotherapy
- + Protein replacement therapies
- + Gene and RNA medicines
- + Rapid-response pandemic countermeasures
One Platform. Multiple Therapeutic Modalities.
From recombinant proteins to VLP vaccines and RNA therapeutics, D-Crypt™ provides a scalable technology foundation for developing the next generation of biologics designed to address global healthcare challenges.
Why D-Crypt™?
Traditional vaccine development often faces challenges related to antigen instability, poor immunogenicity, complex manufacturing, and long development timelines.
D-Crypt™ addresses these limitations through:
Rapid Design and Development
- + Fast incorporation of diverse antigens onto VLP structures
- + Accelerated candidate screening and optimization
- + Reduced development timelines from target selection to preclinical evaluation
Enhanced Immunogenicity
- + Multivalent antigen presentation
- + Strong B-cell activation through repetitive antigen display
- + Potential induction of balanced humoral and cellular immune responses
- + Reduced reliance on high antigen doses
Manufacturing Simplicity
- + Microbial expression system compatible with cost-effective production
- + Scalable and reproducible manufacturing processes
- + Platform-based development approach that reduces process redevelopment
Global Accessibility
- + Designed with affordability and scalability in mind
- + Suitable for both pandemic preparedness and routine immunization programs
- + Potential compatibility with low- and middle-income country manufacturing ecosystems
Platform Applications
D-Crypt™ supports the development of:
Infectious Disease Vaccines
- + Viral pathogens
- + Bacterial pathogens
- + Pandemic preparedness vaccines
- + Emerging and neglected infectious diseases
Therapeutic Vaccines
- + Oncology targets
- + Chronic infectious diseases
- + Immune modulation applications
Combination Vaccine Programs
- + Multivalent vaccine design
- + Broad-spectrum antigen presentation
- + Next-generation vaccine formulations
Advancing a Diverse Pipeline
The D-Crypt™ platform has been successfully applied across multiple vaccine programs, including candidates targeting global health priorities and emerging infectious diseases.
Our current development efforts include programs focused on:
- + Influenza and pandemic preparedness
- + Enteric diseases (Rotavirus)
- + Respiratory pathogens (SARS Cov-2)
- + Global health vaccine opportunities (Rabies vaccine)
The platform’s modular architecture enables rapid adaptation to newly identified threats, making D-Crypt™ a valuable tool for outbreak response and future pandemic preparedness.
Partnership Opportunities
Premas Biotech is actively seeking strategic collaborations for:
- + Co-development partnerships
- + Licensing opportunities
- + Antigen evaluation programs
- + Vaccine innovation initiatives
- + Global health collaborations
- + Regional manufacturing partnerships
Whether you are developing a novel antigen, expanding a vaccine pipeline, or seeking a scalable VLP platform, D-Crypt™ offers a flexible pathway from concept to clinic.
Meet Us at BIO International Convention
Discover how D-Crypt™ can accelerate your vaccine development strategy.
Schedule a meeting with our team to explore partnership opportunities, platform access, and collaborative development programs.
Premas Biotech is Innovating the Future of Vaccines Through Platform Science.